Expert Insights into the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia

A panel of three, renowned oncologists discuss the evolving landscape of CAR-T cell therapies for adult patients with relapsed or refractory acute lymphoblastic leukemia after receiving two or more lines of prior therapy.

EP. 1: Faculty Introductions

December 22nd 2023

Panelist introductions by Gregory Roloff, MD from the University of Chicago Comprehensive Cancer Center, Chicago, Illinois; Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, New York; and Bijal Shah, MD, from the Moffitt Cancer Center, Tampa, Florida.

EP. 2: Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL

January 26th 2024

Faculty review the objectives of the 2023 ASH Insights Program on the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia.

EP. 3: Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL

January 26th 2024

Drs. Roloff, Park, and Shah provide a brief overview of the current, CAR-T cell therapeutic landscape for relapsed or refractory acute lymphoblastic leukemia in adults with a particular focus on those who have completed two or more lines of prior therapy.

EP. 4: Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial

January 26th 2024

Dr. Bijal and colleagues discuss the objectives, clinical outcomes, and safety profile of the Phase 2 ZUMA 3 clinical trial, which evaluated treatment of adult patients with relapsed or refractory, B-precursor, acute lymphoblastic leukemia with the anti-CD-19/anti-CD20 bispecific CAR-T cell therapy, KTE-X19 (brexucabtagene autoleucel).

EP. 5: Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease

February 2nd 2024

Panelists evaluate PFS, OS, and the prognostic significance of negative MRD.

EP. 6: Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion

February 2nd 2024

Dr. Roloff and colleagues offer expert opinion on optimizing treatment sequences for patients with relapsed or refractory ALL who have received two or more prior lines of therapy and the disease and patient factors that inform their treatment plans.

EP. 7: Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)

February 9th 2024

Dr. Roloff and faculty assess outcomes from the retrospective, multicenter ROCCA analysis (Real-world Outcomes Collaborative of CAR-T in Adult ALL) and propose some social determinants of health SDoH variables that bear further investigation.

EP. 8: Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy

February 9th 2024

Dr. Park and co-panelists review the patient and disease characteristics, including patient age, high pre-apheresis disease burden, and bridging response to inotuzumab or blinatumomab among other variables that might best support consideration of post-CART19 maintenance therapy.

EP. 9: Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL

February 16th 2024

Dr. Shah and colleagues dissect the social determinants of health, including limited personal resources, frailty, distance to treatment facilities, therapeutic compliance, and other considerations that impact effective treatment sequencing for patients with relapsed or refractory ALL, including access to care and CAR-T cell availability.

EP. 10: Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia

February 16th 2024

Dr. Shah and faculty provide updates on emerging therapies, which exhibit promise for the treatment of relapsed or refractory acute lymphoblastic leukemia such as tisagenlecleucel and Obe-cel; obecabtagene autoleucel, preliminary outcomes of which were presented in the FELIX study at the 65th ASH Annual Meeting.